$ATOS
ATOSSA THERAPEUTICS, INC.

2020 Q3 Form 10-Q Financial Statement

#000143774920017738 Filed on August 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.850M $2.280M $1.720M
YoY Change 14.91% -51.18% 36.51%
% of Gross Profit
Research & Development $1.659M $1.653M $900.0K
YoY Change -1.49% -36.7% 5.88%
% of Gross Profit
Depreciation & Amortization $20.00K $10.00K $10.00K
YoY Change 100.0% -50.0% 0.0%
% of Gross Profit
Operating Expenses $3.509M $3.936M $2.620M
YoY Change 6.39% -45.98% 24.17%
Operating Profit -$3.509M -$3.936M
YoY Change 6.39% -45.98%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $17.75K $29.67K $0.00
YoY Change 44.46% 26.02% -100.0%
Pretax Income -$3.491M -$3.906M -$2.620M
YoY Change 6.24% -46.22% 25.96%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.491M -$3.906M -$2.620M
YoY Change 6.24% -46.22% 25.96%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$343.5K -$425.5K -$286.7K
COMMON SHARES
Basic Shares Outstanding 10.40M 9.131M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.100M $7.500M $12.60M
YoY Change -40.52% -56.14% 21.15%
Cash & Equivalents $9.106M $7.463M $12.58M
Short-Term Investments
Other Short-Term Assets $178.9K $264.0K $26.13K
YoY Change 8568.17% 188440.71% -15.55%
Inventory
Prepaid Expenses $1.484M $1.464M $862.3K
Receivables
Other Receivables
Total Short-Term Assets $11.32M $10.06M $14.32M
YoY Change -30.99% -45.28% 23.98%
LONG-TERM ASSETS
Property, Plant & Equipment $25.43K $29.44K $34.35K
YoY Change -35.03% -33.35% -36.96%
Goodwill
YoY Change
Intangibles $173.5K
YoY Change -9.64%
Long-Term Investments
YoY Change
Other Assets $17.22K $17.22K $17.22K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $119.3K $144.0K $170.6K
YoY Change -39.08% -34.88% -0.29%
TOTAL ASSETS
Total Short-Term Assets $11.32M $10.06M $14.32M
Total Long-Term Assets $119.3K $144.0K $170.6K
Total Assets $11.44M $10.21M $14.49M
YoY Change -31.08% -45.16% 23.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $682.6K $1.033M $293.2K
YoY Change 36.13% 224.48% -17.03%
Accrued Expenses $85.17K $92.86K $77.89K
YoY Change -62.22% 73.61% -56.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.565M $1.827M $1.323M
YoY Change 0.07% 76.86% -54.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.565M $1.827M $1.323M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.567M $1.831M $1.334M
YoY Change -0.74% 73.29% -54.25%
SHAREHOLDERS EQUITY
Retained Earnings -$104.4M -$100.9M -$94.07M
YoY Change 14.17% 14.47% 22.44%
Common Stock $113.7M $108.7M $106.6M
YoY Change 7.43% 3.46% 27.98%
Preferred Stock $626.0K $671.0K
YoY Change -7.4% -71.79%
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.871M $8.374M $13.16M
YoY Change
Total Liabilities & Shareholders Equity $11.44M $10.21M $14.49M
YoY Change -31.08% -45.16% 23.63%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q4
OPERATING ACTIVITIES
Net Income -$3.491M -$3.906M -$2.620M
YoY Change 6.24% -46.22% 25.96%
Depreciation, Depletion And Amortization $20.00K $10.00K $10.00K
YoY Change 100.0% -50.0% 0.0%
Cash From Operating Activities -$2.680M -$2.230M -$2.710M
YoY Change 51.41% -10.8% 11.07%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K $0.00
YoY Change 0.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$10.00K $0.00
YoY Change 0.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.320M 350.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.680M -2.230M -2.710M
Cash From Investing Activities 0.000 -10.00K 0.000
Cash From Financing Activities 4.320M 350.0K 0.000
Net Change In Cash 1.640M -1.890M -2.710M
YoY Change -192.66% -24.7% 8.4%
FREE CASH FLOW
Cash From Operating Activities -$2.680M -$2.230M -$2.710M
Capital Expenditures $0.00 -$10.00K $0.00
Free Cash Flow -$2.680M -$2.220M -$2.710M
YoY Change 51.41% -10.84% 13.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1032707
CY2019Q1 atos Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation
AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation
3151944
CY2019Q1 atos Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation
AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation
3151944
atos Change In Stock Based Compensation Liability
ChangeInStockBasedCompensationLiability
atos Change In Stock Based Compensation Liability
ChangeInStockBasedCompensationLiability
1741919
atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
2800000
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
20966
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
-111792
CY2020Q2 atos Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
185000000
CY2020Q2 atos Prepaid Financial Exchange Fees Current
PrepaidFinancialExchangeFeesCurrent
21500
CY2019Q4 atos Prepaid Financial Exchange Fees Current
PrepaidFinancialExchangeFeesCurrent
atos Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
347627
atos Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
CY2020Q2 atos Professional Services Current
ProfessionalServicesCurrent
203919
CY2019Q4 atos Professional Services Current
ProfessionalServicesCurrent
108850
atos Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation
ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation
atos Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation
ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation
3151944
CY2020Q2 atos Research And Development Current
ResearchAndDevelopmentCurrent
948250
CY2019Q4 atos Research And Development Current
ResearchAndDevelopmentCurrent
507733
CY2020Q2 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
760622
CY2019Q4 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
739656
atos Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
374000
atos Stock Issued During Period Shares Warrant Exercised
StockIssuedDuringPeriodSharesWarrantExercised
2800000
CY2019Q1 atos Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
11336710
CY2020Q2 atos Working Capital
WorkingCapital
8200000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
293171
CY2020Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
374282
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
646064
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10395001
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Security12b Title
Security12bTitle
Common Stock, $0.18 par value
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0
CY2020Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
92855
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
77888
CY2020Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
98974
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
82536
CY2020Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
182152
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
170820
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
106998222
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
104912480
CY2020Q2 us-gaap Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
625999
CY2019Q4 us-gaap Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
670999
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
275833
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5318796
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
687752
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1036484
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1036484
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5318796
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1724236
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5594629
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7246371
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3811771
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6407699
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4209598
CY2020Q2 us-gaap Assets
Assets
10205699
CY2019Q4 us-gaap Assets
Assets
14489855
CY2020Q2 us-gaap Assets Current
AssetsCurrent
10061681
CY2019Q4 us-gaap Assets Current
AssetsCurrent
14319266
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7462736
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17058527
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12581136
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12691136
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10490493
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7572736
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17168527
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5118400
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6678034
CY2020Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
7018309
CY2019Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
12316429
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9303878
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9130984
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9303878
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9130984
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
1674686
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1643565
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
45000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
1703000
CY2020Q2 us-gaap Deposit Assets
DepositAssets
14218
CY2019Q4 us-gaap Deposit Assets
DepositAssets
14218
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24711
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27549
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-2226
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-5806
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.44
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
655408
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
899420
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
53125
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
68542
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2282568
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4674121
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4280957
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7287214
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3906142
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7262529
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-244012
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-123589
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
237827
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-30802
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-6704
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-20101
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6853562
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11335836
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
739536
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-35062
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
14967
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-345625
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
602022
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
303335
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
19400
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
40200
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15400
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11500
CY2020Q2 us-gaap Liabilities
Liabilities
1831393
CY2019Q4 us-gaap Liabilities
Liabilities
1333850
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10205699
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14489855
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1826673
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1322742
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font: inherit;">1:</div> NATURE OF OPERATIONS</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> January 6, 2020, </div>we changed our corporate name from Atossa Genetics Inc. to Atossa Therapeutics, Inc.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Atossa Therapeutics, Inc. (the &#x201c;Company&#x201d;) was incorporated on <div style="display: inline; font-style: italic; font: inherit;"> April 30, 2009, </div>in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company's fiscal year ends on <div style="display: inline; font-style: italic; font: inherit;"> December 31.&nbsp;</div>The Company is currently focused on development of its pharmaceuticals for the treatment of the novel coronavirus ("COVID-<div style="display: inline; font-style: italic; font: inherit;">19"</div>), breast cancer and other breast conditions.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 21.45pt 0pt -9pt; text-align: justify; text-indent: 18pt;"><div style="display: inline; font-weight: bold;">Impact of the Novel Coronavirus&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -9pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The continued spread of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is affecting the United States and global economies and <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the Company's operations and those of <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which the Company relies, including&nbsp;causing possible disruptions in the supply of the Company's Endoxifen, AT-<div style="display: inline; font-style: italic; font: inherit;">H201,</div> AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> and the conduct of current and future clinical trials. In addition, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the operations of the U.S.&nbsp;Food and Drug Administration and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. The evolving COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic could also directly or indirectly impact the pace of enrollment in the Company's clinical trials for at least the next several months and possibly longer as patients <div style="display: inline; font-style: italic; font: inherit;"> may </div>avoid or <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be able to travel to healthcare facilities and physicians' offices except for a health emergency. Such facilities and offices <div style="display: inline; font-style: italic; font: inherit;"> may </div>also be required to focus limited resources on non-clinical trial activities, including treatment of COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> patients, and <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be available, in whole or in part, for clinical trial activities&nbsp;related to the Company's products under development. Additionally, while the potential economic impact brought by, and the duration of, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is difficult to assess or predict, the impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic on the global financial markets <div style="display: inline; font-style: italic; font: inherit;"> may </div>reduce the Company's ability to access capital, which could negatively impact the Company's short-term and long-term liquidity. The ultimate impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is highly uncertain and subject to change. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on the Company's liquidity, capital resources, operations, financial position and business and those of the <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which we rely. As of <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020, </div>the Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any delay in drug supply for its ongoing and planned clinical studies,&nbsp;including studies of Endoxifen, AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> and AT-<div style="display: inline; font-style: italic; font: inherit;">H201.</div> Currently, enrollment is open in Australia for the Endixofen Window of Opportunity study for which enrollment continues to be slow due in part to disruption caused by COVID-<div style="display: inline; font-style: italic; font: inherit;">19.</div> The Company anticipates opening enrollment in the AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> trial and the Mammographic Breast Density (&#x201c;MBD&#x201d;) Endoxifen trial in the <div style="display: inline; font-style: italic; font: inherit;">second</div> half of <div style="display: inline; font-style: italic; font: inherit;">2020</div> and will continue to monitor the future enrollment for potential restrictions of site visits, mammograms or the impositions of new restrictions on&nbsp;trials&nbsp;as a result of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In response to the Coronavirus pandemic, the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;) was signed into law on <div style="display: inline; font-style: italic; font: inherit;"> March 27, 2020.&nbsp; </div>The CARES Act, among other things, includes provisions related to refundable payroll tax credits, deferment of employer side social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations, increased limitations on&nbsp;qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.&nbsp; The CARES Act had <div style="display: inline; font-style: italic; font: inherit;">no</div> material impact on the Company's income tax provision for the <div style="display: inline; font-style: italic; font: inherit;">three</div>&nbsp;and <div style="display: inline; font-style: italic; font: inherit;">six</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">30,</div> <div style="display: inline; font-style: italic; font: inherit;">2020.</div>&nbsp; The Company continues to examine the elements of the CARES Act and the impact it <div style="display: inline; font-style: italic; font: inherit;"> may </div>have on its financial position, results of operations and cash flows.</div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
347627
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11336710
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6610
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7625
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5459417
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4651051
us-gaap Net Income Loss
NetIncomeLoss
-6853562
us-gaap Net Income Loss
NetIncomeLoss
-11335836
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3906142
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7262529
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4073307
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2947420
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3906142
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7262529
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6853562
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11335836
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
3935807
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
7286069
us-gaap Operating Expenses
OperatingExpenses
6872816
us-gaap Operating Expenses
OperatingExpenses
11350398
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3935807
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7286069
us-gaap Operating Income Loss
OperatingIncomeLoss
-6872816
us-gaap Operating Income Loss
OperatingIncomeLoss
-11350398
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
14700
us-gaap Operating Lease Expense
OperatingLeaseExpense
29400
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
39515
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
39371
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4720
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11108
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
14700
us-gaap Operating Lease Payments
OperatingLeasePayments
29400
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
14200
us-gaap Operating Lease Payments
OperatingLeasePayments
28200
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44235
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
50479
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.113
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y146D
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
263957
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
26130
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17218
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17218
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6188
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12892
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29665
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23540
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19254
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14562
CY2020Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
11560
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4792
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6610
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7625
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
626
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
671
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
626
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
671
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
1
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
1
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1464366
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
862344
CY2020Q2 us-gaap Prepaid Insurance
PrepaidInsurance
251455
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
222476
CY2020Q2 us-gaap Prepaid Rent
PrepaidRent
13464
CY2019Q4 us-gaap Prepaid Rent
PrepaidRent
4275
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2019Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11300000
CY2020Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11336710
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29440
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34350
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1653239
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2611948
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2591859
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4063184
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100924602
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94071040
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1031669
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4163814
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2915000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
651000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15214250
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4308383
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7223383
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.44
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.72
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
15214250
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7223383
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.72
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.66
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8821400
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y200D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y18D
CY2019Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
347627
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1724236
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
5594629
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
8805010
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
19496190
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
17552457
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
13156005
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
10896337
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
8374306
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Use of Estimates:</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div>
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9187588
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9126153
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9159286
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7852907

Files In Submission

Name View Source Status
0001437749-20-017738-index-headers.html Edgar Link pending
0001437749-20-017738-index.html Edgar Link pending
0001437749-20-017738.txt Edgar Link pending
0001437749-20-017738-xbrl.zip Edgar Link pending
atos-20200630.xml Edgar Link completed
atos-20200630.xsd Edgar Link pending
atos-20200630_cal.xml Edgar Link unprocessable
atos-20200630_def.xml Edgar Link unprocessable
atos-20200630_lab.xml Edgar Link unprocessable
atos-20200630_pre.xml Edgar Link unprocessable
atos20200630_10q.htm Edgar Link pending
ex_194900.htm Edgar Link pending
ex_194901.htm Edgar Link pending
ex_194902.htm Edgar Link pending
ex_194903.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending